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Abstract
Introduction: Pulmonary hypertension (PHT) is a common complication in 
β-thalassemia. We aimed to determine the prevalence of PHT and its main indicators in 
patients with β thalassemia Major (TM) and β-thalassemia Intermedia (TI), considering 
left ventricular function.
Methods: Pulmonary hypertension (PHT) is a common complication in β-thalassemia. 
We aimed to determine the prevalence of PHT and its main indicators in patients with β 
thalassemia Major (TM) and β-thalassemia Intermedia (TI), considering left ventricular 
function.
Results: The overall prevalence of PHT in TM and TI group was estimated to be 35.2% 
and 29.3%, respectively; while reduced LVEF was evident in 22.7% and 10.1% of patients 
with TM and TI, respectively. No significant correlation was observed between mean 
PAP and LVEF in the patients with TI (Pearson coefficient = -0.096, P value = 0.345); 
while, an adverse association was revealed between mean PAP and LVEF in patients with 
TM (Pearson coefficient = -0.227, P value = 0.033). Upon univariate analysis, the only 
significant association was observed between LVEF and pulmonary hypertension among 
TM patients (P value = 0.001).Our results did not indicate that male gender and aging may 
affect the development of PHT.
Conclusions: According to our findings, a considerable proportion of patients with TM 
and TI may have PHT. We detected an adverse association between mean PAP and LVEF 
in patients with TM. Left ventricular function was reduced in patients with PHT among 
TM group.
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INTRODUCTION
β-thalassemia is an inherited hemoglobin disorder which 
results in chronic hemolytic anemia. Depending on the 
clinical severity, two forms are distinguished, including 
β-thalassemia Major (TM) and β-thalassemia Intermedia 
(TI) [1]. While TM is characterized by severe anemia 
starting from the first year of life and therefore requiring 
lifelong transfusion therapy for survival, the TI form has 
a later clinical onset with a milder anemia that permits 
survival without regular transfusions and a longer life ex-
pectancy [2-4]. The diverse clinical severity of TM and 
TI and the different therapeutic approaches lead to a wide 
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status in these types of β-thalassemia are not completely 
comparable in both forms [5, 6]. 
With regard to the cardiac complications of β-thalassemia, 
Pulmonary Hypertension (PHT) is a common complica-
tion, especially among patients with TI [7]. It is consid-
ered to be the primary cause of congestive heart failure in 
such patients [8]. However, the majority of patients with 
increased Pulmonary Arterial Pressure (PAP) are asymp-
tomatic [9]. Even, most of the patients may have normal 
left ventricular function in spite of severe PHT. Therefore, 
this condition is often unrecognized until patients devel-
op heart failure and/or hypoxemia [10-12].
There is paucity of data regarding the prevalence of PHT 
in both forms of β-thalassemia and also its main determi-
nants. In this line, the present study aimed to determine 
the prevalence of PHT and identify its main indicators in 
patients with TM or TI, considering normal or reduced 
left ventricular function. 
METHODS
In this cross-sectional study performed at Firoozgar Hospi-
tal and Zafar Thalassemia Center in Tehran, patients with 
TM or TI referred between January 2009 and May 2009 
were selected by simple sequential non-random sampling 
and enrolled into the study. In general, 187 consecutive 
patients without previous history of any cardiovascular 
or pulmonary disease (i.e. chronic obstructive pulmonary 
disease or ischemic heart disease) were selected. The Insti-
tutional Review Board (IRB) of Iran University of Medical 
Sciences (IUMS) approved the study protocol and patients 
provided informed written consent. Baseline characteristics 
including demographics and disease duration were collect-
ed by interviewing or reviewing medical records. Then, all 
participants were referred to Firoozgar Hospital for echo-
cardiography evaluation in order to determine Pulmonary 
Artery Pressure (PAP) and Left Ventricular Ejection Frac-
tion (LVEF). In this regard, PHT was defined as mean PAP 
higher than 25 mmHg. Also LVEF less than 50% was con-
sidered as left ventricular dysfunction in β-thalassemia pa-
tients. Echocardiography was performed by the same phy-
sician for all of the patients. Results were reported as mean 
± standard deviation (SD) for the quantitative variables 
and percentages for the categorical variables. The groups 
were compared using the Student’s t-test for the continu-
ous variables and the chi-square test (or Fisher’s exact test 
if required) for the categorical variables. Odds ratio (OR) 
and 95% confidence intervals (CI) were calculated. Asso-
ciation between the quantitative variables was examined by 
the Pearson’s correlation coefficient test. P values of 0.05 or 
less were considered statistically significant. All the statisti-
cal analyses were performed using SPSS version 13.0 (SPSS 
Inc. Released 2005. SPSS for Windows, Version 13.0. Chi-
cago, SPSS Inc.).
RESULTS
In the present study, 187 patients -88 in TM group and 
99 in TI group - were studied among whom 46.6% and 
50.5% were male, respectively. Patients in the TM group 
were significantly younger compared to the TI group (P 
value < 0.001). Table 1 shows some of the demographic 
and clinical characteristics of the patients in both groups.
The overall prevalence of PHT in TM and TI groups was 
35.2% and 29.3%, respectively. Left ventricular dysfunc-
tion based on reduced LVEF was also evident in 22.7% 
and 10.1% of patients with TM and TI, respectively. In 
patients with TI, prevalence of PHT in the subgroup with 
normal LVEF was 21.3% and in those with reduced ven-
tricular function was 20.0% (P value = 0.921). In fact, the 
linear correlation between PAP and LVEF was not signif-
icant (Pearson coefficient = -0.096, P value = 0.345). In 
TM group, the overall prevalence of PHT in normal left 
ventricular function group was 13.2% and in left ventric-
ular dysfunction group was 25% (P value = 0.294); while, 
an inverse correlation was revealed between mean PAP 
and LVEF in this group of patients (Pearson coefficient = 
-0.227, P value = 0.033). Table 2 shows the univariate as-
sociation of PHT with gender, age and LVEF among both 
TM and TI patients. In this regard, the only significant as-
sociation was observed between LVEF and PHT among 
TM patients (P value = 0.001).
Table 1: Comparison of demographics as well as pulmonary artery pressure (PAP) and left ventricular ejection fraction among thalas-
semia major (TM) and thalassemia intermedia (TI) groups (TM: thalassemia major, TI: thalassemia intermedia, PAP: pulmonary artery 
pressure, LVEF: left ventricular ejection fraction). 
Variable TM TI P value
Sex 0.66
Male 41 (46.6) 50 (50.5)
Female 47 (53.4) 49 (49.5)
Age (y) 24.93 ± 5.56 33.28 ± 11.23 0.001
PAP (mmHg) 31.4 ± 11.08 34.26 ± 18.08 0.20
LVEF (%) 55.81 ± 13.21 58.85 ± 9.53 0.07
Data are presented as mean SD and No. (%).
TM: Beta-thalassemia major; TI: Thalassaemia intermedia; PAP: Pulmonary Artery Pressure; LVEF: Left ventricular ejection fraction
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Table 2: The Univariate associations between Pulmonary Hypertension (defined as PAP>25 mmHg) and Gender, Age and LVEF among 
thalassemia major (TM) and thalassemia intermedia (TI) patients (TM: thalassemia major, TI: thalassemia intermedia, LVEF: left ven-
tricular ejection fraction, PAP: pulmonary artery pressure).
TM TI
PAP > 25 mmHg PAP < 25 mmHg P value PAP > 25 mmHg PAP < 25 mmHg P value
Sex 0.84 0.55
Male 14 27 16 34
Female 17 30 13 36
Age( y) 24.1 ± 5.2 25.4 ± 7.2 0.42 30.5 ± 11.4 34.5 ± 10.9 0.13
LVEF (%) 53.0 ± 14.9 60.8 ± 7.0 0.001 54.9 ± 9.8 58.6 ± 9.4 0.67
Data are presented as mean SD and No. (%).
TM: Beta-thalassemia major; TI: Thalassaemia intermedia; LVEF: Left ventricular ejection fraction
DISCUSSION
In this study, the prevalence of PHT in the TM group was 
35.2% and in the TI group was 29.3%, which was not sig-
nificantly different. The obtained prevalence of PHT in our 
survey was in the range published in most of the previous re-
ports. In a study by Vlahos et al. [13], PHT was observed in 
18.5% of TM patients and in another study by Aessopos et 
al. [14], PHT prevalence was estimated to be 23% in patients 
with TI. Generally speaking, it could be concluded that PHT 
is a partially common finding in both forms of thalassemia, 
even more frequent in TI patients.
Another important finding of our study was that PAP and 
LVEF were not associated in our patients. Also, the prev-
alence of PHT is independent to left ventricular function 
state in both types of β-thalassemia. Thus, prevalence of 
PHT in patients with normal left ventricular function and 
those with impaired ventricular function is not different 
that is consistent with most of the previous studies. Vlahos 
et al. [13] similarly showed that despite normal systolic and 
diastolic ventricular function, 18.5% of TM patients had 
PHT. In another study by Aessopos et al. [14], despite the 
high prevalence of PHT 60%, right heart failure was detect-
ed in only 5% of patients and left ventricular dysfunction 
was reported in none. Aessopos also indicated no cases of 
left ventricular dysfunction in thalassemia patients with 
PHT [4]. Also, upon univariate analysis of our data, the 
only significant association was observed between LVEF 
and pulmonary hypertension among TM patients. Our re-
sults did not indicate that male gender and aging may affect 
the development of PHT. 
In summary, our obtained prevalence of PHT is reported in 
most of the previous observations and a considerable propor-
tion of patients in both TM and TI groups had PHT that was 
more prevalent in the former group. We detected an adverse 
association between mean PAP and LVEF in patients with 
TM. Left ventricular function was reduced in patients with 
PHT among TM group.
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